{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:45:20Z","timestamp":1792514720002,"version":"4.5.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,12]]},"abstract":"\n Background:<\/jats:title>\n Etrasimod is an oral sphingosine-1-phosphate receptor modulator evaluated for induction and maintenance therapy in moderately to severely active ulcerative colitis (UC). This meta-analysis aimed to assess the efficacy and safety of etrasimod in adults with active UC.<\/jats:p>\n <\/jats:sec>\n \n Objectives:<\/jats:title>\n To assess the efficacy and safety of etrasimod as induction and maintenance therapy in adults with moderately to severely active UC.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing etrasimod with placebo in adults (\u226518 years) with moderately to severely active UC was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov through November 2025. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with\n I<\/jats:italic>\n 2<\/jats:sup>\n and \u03c7\n 2<\/jats:sup>\n statistics. Analyses were performed with RevMan 5.4.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Four RCTs, including 1239 patients (etrasimod = 826; placebo = 413) were analyzed. At 12 weeks, etrasimod significantly improved clinical remission (RR = 2.92, 95% CI 1.71-4.98;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 57%), clinical response (RR = 1.71, 95% CI 1.46-2.02;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 19%), endoscopic improvement (RR = 1.72, 95% CI 1.30-2.27;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 36%), and mucosal healing (RR = 3.11, 95% CI 1.72-5.62;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 54%). Beyond 40 weeks, etrasimod increased clinical remission (RR = 4.28, 95% CI 2.72-6.73;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%), clinical response (RR = 2.20, 95% CI 1.74-2.78;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%), endoscopic improvement (RR = 3.51, 95% CI 2.36-5.23;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%), mucosal healing (RR = 6.93, 95% CI 3.61-13.33;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%), and steroid-free remission (RR = 4.28, 95% CI 2.72-6.73;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%). Any treatment-emergent adverse event was slightly higher with etrasimod (RR = 1.15, 95% CI 1.04-1.28;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0%), while serious adverse events (RR = 0.79, 95% CI 0.39-1.61;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 38%) and discontinuations due to adverse events (RR = 2.17, 95% CI 0.54-8.67;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 50%) did not differ significantly.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance:<\/jats:title>\n Etrasimod is effective in inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC, with an acceptable safety profile.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10600280261429462","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:12:16Z","timestamp":1774606336000},"page":"1156-1173","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1177","volume":"60","author":[{"given":"Anurag","family":"Jha","sequence":"first","affiliation":[{"name":"King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4688-4057","authenticated-orcid":false,"given":"Nirmal","family":"Paudel","sequence":"additional","affiliation":[{"name":"Nishtar Medical University, Multan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawaja Arham","family":"Jawaid","sequence":"additional","affiliation":[{"name":"Sharif Medical City Hospital, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Haad Munir","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Ali","sequence":"additional","affiliation":[{"name":"Wah Medical College, Wah Cantonment, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Javaid","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Sharif","sequence":"additional","affiliation":[{"name":"Lahore General Hospital, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Asghar","sequence":"additional","affiliation":[{"name":"FMH College of Medicine and Dentistry, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saad","sequence":"additional","affiliation":[{"name":"Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.02.004"},{"key":"e_1_3_4_3_2","volume-title":"Ulcerative Colitis","author":"Lynch WD","year":"2025","unstructured":"Lynch WD, Hsu R. Ulcerative Colitis. StatPearls Publishing; 2025."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-020-00246-4"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.22037\/ghfbb.v18i2.3105"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04234.x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1987779"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-823066"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.033"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12841"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","unstructured":"Afzali A Lukanova R Hennessy F et al. Unmet needs in real-world advanced therapy-na\u00efve and -experienced patients with moderately to severely active ulcerative colitis in the United States. Adv Ther. 2023;40:4321-4338. Accessed December 12 2025. https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02605-y","DOI":"10.1007\/s12325-023-02605-y"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113890"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502363"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201810001-00569"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-BSG.195"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00213"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebm.13.6.162-a"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00198-0"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002250"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039372"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1420455"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0255"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-001838"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155014"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1235656"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","unstructured":"Wang X Chen X Xiang H et al. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med. 2021;25:2740-2749. Accessed December 12 2025. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.16333","DOI":"10.1111\/jcmm.16333"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001516"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2397650"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000543.pub5"},{"key":"e_1_3_4_33_2","unstructured":"Al Kazzi ES. The updated 2025 ACG guidelines to manage adult ulcerative colitis patients. Accessed December 12 2025. https:\/\/gi.org\/journals-publications\/ebgi\/alkazzi_aug2025\/"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1565889"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00155"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131722"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100096"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0193"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261429462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261429462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261429462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:17Z","timestamp":1792513037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261429462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1177\/10600280261429462"],"URL":"https:\/\/doi.org\/10.1177\/10600280261429462","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}